Maintenance of symptomatic remission in patients with Crohn's disease.
Crohn's disease is a chronic inflammatory intestinal disorder characterized in most patients by repeated episodes of diminished and exacerbated symptoms. Recent controlled trials demonstrated that oral preparations of 5-aminosalicylic acid decrease recurrence rates by approximately 40% when administered long-term to patients with quiescent Crohn's disease. Orally administered corticosteroids, sulfasalazine, metronidazole, azathioprine, and cyclosporine have not proved of benefit in the prevention of recurrences of Crohn's disease. Nonetheless, corticosteroids, metronidazole, and azathioprine can control chronically active disease. Methotrexate may have some benefit in the treatment of active Crohn's disease, but its role in maintenance of remission has not been investigated. Elimination diets seem to prolong periods of symptomatic remission. Further studies are needed to define subgroups of patients who are most likely to benefit from preventive therapy.
Stark
M E
ME
Division of Gastroenterology and Internal Medicine, Mayo Clinic Jacksonville, Florida.
Tremaine
W J
WJ
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000178:diet therapy / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D015122:Mercaptopurine / Q000627:therapeutic use; D019804:Mesalamine; D008727:Methotrexate / Q000627:therapeutic use; D012008:Recurrence; D012074:Remission Induction; D012460:Sulfasalazine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000636:Aminosalicylic Acids; D012460:Sulfasalazine; D019804:Mesalamine; D016572:Cyclosporine; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate